SELLAS Life Sciences Group, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SLS Nasdaq 2836 www.sellaslifesciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SELLAS Life Sciences Group, Inc.

A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement - Jan 14th, 2026 5:18 pm
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe - Jan 14th, 2026 6:30 am
SELLAS Life Sciences Group (SLS) Is Up 50.8% After REGAL Trial Nears Final OS Trigger - Has The Bull Case Changed? - Jan 5th, 2026 8:12 pm
Social Buzz: Wallstreetbets Stocks Advance Premarket Monday; SELLAS Life Sciences Group, Chevron to Open Higher - Jan 5th, 2026 4:47 am
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Dec 29th, 2025 6:35 am
Assessing SELLAS Life Sciences Group (SLS) Valuation After Positive Leukemia Data and Supportive FDA Designations - Dec 25th, 2025 9:23 am
Why SELLAS Life Sciences Group (SLS) Is Up 12.6% After Encouraging SLS009 Phase 2 AML Data And What's Next - Dec 10th, 2025 8:09 pm
High Growth Tech Stocks to Watch in US December 2025 - Dec 9th, 2025 4:38 am
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 - Dec 7th, 2025 4:00 pm
SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 12th, 2025 2:05 pm
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting - Nov 3rd, 2025 7:00 am
Sellas Life Sciences Group Inc. (SLS) Advances Cancer Pipeline with $31M Funding and Upcoming R&D Showcase - Oct 29th, 2025 9:57 am
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds - Oct 27th, 2025 6:30 am
SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum - Oct 22nd, 2025 7:00 am
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 - Oct 13th, 2025 6:00 am
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update - Sep 30th, 2025 6:30 am
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds - Sep 11th, 2025 6:30 am
SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 12th, 2025 2:05 pm
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification - Aug 7th, 2025 6:30 am
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised) - Jul 31st, 2025 5:02 pm